RATIONALE: Assays of schedule-controlled responding can be used to characterize the pharmacology of benzodiazepines and other GABAA receptor modulators, and are sensitive to changes in drug effects that are related to physical dependence. OBJECTIVE: The present study used this approach to investigate the role of GABAA receptor subtypes in mediating dependence-like effects following benzodiazepine administration. METHODS: Squirrel monkeys (n = 6) were trained on a fixed-ratio schedule of food reinforcement. Initially, the response rate-decreasing effects of chlordiazepoxide (0.1-10 mg/kg; nonselective GABAA receptor agonist), zolpidem (0.032-1.0 mg/kg; α1 subunit-containing GABAA subtype-preferring agonist), and HZ-166 (0.1-10 mg/kg; functionally selective α2 and α3 subunit-containing GABAA receptor agonist) were assessed. Next, acute dependence-like effects following single injections of chlordiazepoxide, zolpidem, and HZ-166 were assessed with flumazenil (0.1-3.2 mg/kg; nonselective GABAA receptor antagonist). Finally, acute dependence-like effects following zolpidem administration were assessed with βCCt and 3-PBC (0.1-3.2 mg/kg and 0.32-10 mg/kg, respectively; α1 subunit-containing GABAA receptor antagonists). RESULTS: Chlordiazepoxide, zolpidem, and HZ-166 produced dose- and time-dependent decreases in response rates, whereas flumazenil, βCCT, and 3-PBC were ineffective. After the drug effects waned, flumazenil produced dose-dependent decreases in response rates following administration of 10 mg/kg chlordiazepoxide and 1.0 mg/kg zolpidem, but not following any dose of HZ-166. Further, both βCCT and 3-PBC produced dose-dependent decreases in response rates when administered after 1.0 mg/kg zolpidem. CONCLUSIONS: These data raise the possibility that α1 subunit-containing GABAA receptors play a major role in physical dependence-related behaviors following a single injection of a benzodiazepine.
RATIONALE: Assays of schedule-controlled responding can be used to characterize the pharmacology of benzodiazepines and other GABAA receptor modulators, and are sensitive to changes in drug effects that are related to physical dependence. OBJECTIVE: The present study used this approach to investigate the role of GABAA receptor subtypes in mediating dependence-like effects following benzodiazepine administration. METHODS: Squirrel monkeys (n = 6) were trained on a fixed-ratio schedule of food reinforcement. Initially, the response rate-decreasing effects of chlordiazepoxide (0.1-10 mg/kg; nonselective GABAA receptor agonist), zolpidem (0.032-1.0 mg/kg; α1 subunit-containing GABAA subtype-preferring agonist), and HZ-166 (0.1-10 mg/kg; functionally selective α2 and α3 subunit-containing GABAA receptor agonist) were assessed. Next, acute dependence-like effects following single injections of chlordiazepoxide, zolpidem, and HZ-166 were assessed with flumazenil (0.1-3.2 mg/kg; nonselective GABAA receptor antagonist). Finally, acute dependence-like effects following zolpidem administration were assessed with βCCt and 3-PBC (0.1-3.2 mg/kg and 0.32-10 mg/kg, respectively; α1 subunit-containing GABAA receptor antagonists). RESULTS:Chlordiazepoxide, zolpidem, and HZ-166 produced dose- and time-dependent decreases in response rates, whereas flumazenil, βCCT, and 3-PBC were ineffective. After the drug effects waned, flumazenil produced dose-dependent decreases in response rates following administration of 10 mg/kg chlordiazepoxide and 1.0 mg/kg zolpidem, but not following any dose of HZ-166. Further, both βCCT and 3-PBC produced dose-dependent decreases in response rates when administered after 1.0 mg/kg zolpidem. CONCLUSIONS: These data raise the possibility that α1 subunit-containing GABAA receptors play a major role in physical dependence-related behaviors following a single injection of a benzodiazepine.
Authors: John R Atack; Keith A Wafford; Spencer J Tye; Susan M Cook; Bindi Sohal; Andrew Pike; Cyrille Sur; David Melillo; Linda Bristow; Fran Bromidge; Ian Ragan; Julie Kerby; Les Street; Robert Carling; José L Castro; Paul Whiting; Gerard R Dawson; Ruth M McKernan Journal: J Pharmacol Exp Ther Date: 2005-09-23 Impact factor: 4.030
Authors: James K Rowlett; Donna M Platt; Snjezana Lelas; John R Atack; Gerard R Dawson Journal: Proc Natl Acad Sci U S A Date: 2005-01-11 Impact factor: 11.205
Authors: Miroslav M Savić; Samarpan Majumder; Shengming Huang; Rahul V Edwankar; Roman Furtmüller; Srdan Joksimović; Terry Clayton; Joachim Ramerstorfer; Marija M Milinković; Bryan L Roth; Werner Sieghart; James M Cook Journal: Prog Neuropsychopharmacol Biol Psychiatry Date: 2010-01-13 Impact factor: 5.067
Authors: Bradford D Fischer; Raymond J Schlitt; Bryan Z Hamade; Sabah Rehman; Margot Ernst; Michael M Poe; Guanguan Li; Revathi Kodali; Leggy A Arnold; James M Cook Journal: Brain Res Bull Date: 2017-03-04 Impact factor: 4.077
Authors: Lais F Berro; Daniela Rüedi-Bettschen; Jemma E Cook; Lalit K Golani; Guanguan Li; Rajwana Jahan; Farjana Rashid; James M Cook; James K Rowlett; Donna M Platt Journal: Alcohol Clin Exp Res Date: 2019-04-08 Impact factor: 3.455
Authors: Bradford D Fischer; Donna M Platt; Sundari K Rallapalli; Ojas A Namjoshi; James M Cook; James K Rowlett Journal: Drug Alcohol Depend Date: 2015-10-30 Impact factor: 4.492
Authors: Jovana Kovačević; Tamara Timić; Veera V Tiruveedhula; Bojan Batinić; Ojas A Namjoshi; Marija Milić; Srđan Joksimović; James M Cook; Miroslav M Savić Journal: Brain Res Bull Date: 2014-03-30 Impact factor: 4.077
Authors: Angela N Duke; V V N Phani Babu Tiruveedhula; Dishary Sharmin; Daniel E Knutson; James M Cook; Donna M Platt; James K Rowlett Journal: Drug Alcohol Depend Date: 2021-08-27 Impact factor: 4.492